These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 10102291)

  • 1. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
    Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
    Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.
    Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR
    J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
    Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
    J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
    Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
    Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
    Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-18 not required for IRBP peptide-induced EAU: studies in gene-deficient mice.
    Jiang HR; Wei X; Niedbala W; Lumsden L; Liew FY; Forrester JV
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):177-82. PubMed ID: 11133864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment.
    Silver PB; Chan CC; Wiggert B; Caspi RR
    Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2898-905. PubMed ID: 10549650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.
    Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR
    Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12.
    Yokoi H; Kato K; Kezuka T; Sakai J; Usui M; Yagita H; Okumura K
    Eur J Immunol; 1997 Mar; 27(3):641-6. PubMed ID: 9079803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
    Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
    Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
    Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.
    Okunuki Y; Usui Y; Nagai N; Kezuka T; Ishida S; Takeuchi M; Goto H
    Invest Ophthalmol Vis Sci; 2009 May; 50(5):2255-61. PubMed ID: 19136706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.
    Avichezer D; Silver PB; Chan CC; Wiggert B; Caspi RR
    Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):127-31. PubMed ID: 10634611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis.
    Suzuki J; Sakai J; Okada AA; Takada E; Usui M; Mizuguchi J
    Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):314-21. PubMed ID: 11981647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staphylococcal enterotoxin B is involved in aggravation and recurrence of murine experimental autoimmune uveoretinitis via Vbeta8+CD4+ T cells.
    Kohno H; Sakai T; Tsuneoka H; Imanishi K; Saito S
    Exp Eye Res; 2009 Oct; 89(4):486-93. PubMed ID: 19523946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis.
    Xu H; Rizzo LV; Silver PB; Caspi RR
    Cell Immunol; 1997 May; 178(1):69-78. PubMed ID: 9184700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody.
    Zhang R; Qian J; Guo J; Yuan YF; Xue K
    Curr Eye Res; 2009 Apr; 34(4):297-303. PubMed ID: 19373578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy ameliorates induction and expression of experimental autoimmune uveitis.
    Agarwal RK; Chan CC; Wiggert B; Caspi RR
    J Immunol; 1999 Mar; 162(5):2648-54. PubMed ID: 10072507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice.
    Iwata D; Kitaichi N; Miyazaki A; Iwabuchi K; Yoshida K; Namba K; Ozaki M; Ohno S; Umezawa K; Yamashita K; Todo S; Ishida S; Onoé K
    Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2077-84. PubMed ID: 19907030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide.
    Keino H; Kezuka T; Takeuchi M; Yamakawa N; Hattori T; Usui M
    Arch Ophthalmol; 2004 Aug; 122(8):1179-84. PubMed ID: 15302659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.